10x Genomics Announces Launch of a Follow-On Public Offering
September 08 2020 - 4:21PM
10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced
that the Company has commenced an underwritten public offering of
3,500,000 shares of the Company’s Class A common stock to be issued
by the Company pursuant to a registration statement filed with the
Securities and Exchange Commission. All of the shares are being
offered by the Company. Additionally, the Company intends to grant
the underwriters a 30-day option to purchase up to 525,000
additional shares of the Company’s Class A common stock.
The offering is being made through an underwriting group led by
J.P. Morgan Securities LLC, BofA Securities and Cowen and Company,
LLC. Stifel and William Blair are acting as co-managers for the
offering.
A registration statement on Form S-1, including a prospectus,
which is preliminary and subject to completion, relating to these
securities has been filed with the Securities and Exchange
Commission but has not yet become effective. These securities may
not be sold, nor may offers to buy be accepted, prior to the time
the registration statement becomes effective. This press release
shall not constitute an offer to sell or a solicitation of an offer
to buy these securities, nor shall there be any sale of these
securities in any state in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
The offering of these securities may be made only by means of a
prospectus. Copies of the preliminary prospectus may be obtained by
contacting: J.P. Morgan Securities LLC, Attention: Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717,
by telephone at 1-866-803-9204 or by email at
prospectus-eq_fi@jpmchase.com; BofA Securities, NC1-004-03-43, 200
North College Street, 3rd floor, Charlotte, NC 28255-0001,
Attention: Prospectus Department, or by email at
dg.prospectus_requests@bofa.com and Cowen and Company, LLC,
c/o Broadridge Financial Solutions, Attention: Prospectus
Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by
telephone at (833) 297-2926, or by email at
PostSaleManualRequests@broadridge.com.
About 10x Genomics
10x Genomics, Inc. is a life science technology
company building products to interrogate, understand and master
biology.
Forward-looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
as contained in Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Forward-looking statements generally can be identified by
the use of forward-looking terminology such as “may,” “will,”
“should,” “expect,” “plan,” “anticipate,” “could,” “intend,”
“target,” “project” “contemplate,” “believe,” “estimate,”
“predict,” “potential” or “continue” or the negatives of these
terms or variations of them or similar terminology. These
forward-looking statements involve risks and uncertainties that
could cause 10x Genomics, Inc.’s actual results to differ
materially from those expressed in these forward-looking
statements. These and additional risks and uncertainties that could
affect 10x Genomics, Inc.’s financial and operating results and
cause actual results to differ materially from those indicated by
the forward-looking statements made in this press release include
those discussed under the captions “Risk Factors” and “Management's
Discussion and Analysis of Financial Condition and Results of
Operation” and elsewhere in its Annual Report on Form 10-K for the
year ended December 31, 2019 and Quarterly Report on Form 10-Q for
the quarters ended June 30, 2020 and March 31, 2020, as well as in
its other reports filed with the Securities and Exchange
Commission, including the registration statement relating to the
proposed offering. The Company’s prospectus and periodic filings
are accessible on the SEC’s website at www.sec.gov. The
forward-looking statements in this press release are based on
information available to 10x Genomics, Inc. as of the date hereof,
and 10x Genomics, Inc. disclaims any obligation to update any
forward-looking statements provided to reflect any change in its
expectations or any change in events, conditions, or circumstances
on which any such statement is based, except as required by law.
These forward-looking statements should not be relied upon as
representing 10x Genomics, Inc.’s views as of any date subsequent
to the date of this press release.
Contacts:
Investorsinvestors@10xgenomics.com
Mediamedia@10xgenomics.com
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Apr 2023 to Apr 2024